9th Annual Clinical Trial Performance Metrics

2012 Highlights:

• Full programme endorsement by the Metrics Champion Consortium (MCC) to include a keynote update on current MCC activities
• Understanding the use of metrics to measure and ultimately improve partnerships between vendors and sponsors including EMD Serono Inc. and Merck Serono
• Evaluate the true value of benchmarking with an introduction to McKinsey & Co’s IMPACT tool and a chance to discuss the industries' perspectives on such databases
• 10+ industry driven case studies

Comments from previous delegates:

• “I’ve really enjoyed the conference content plus opportunity to network” GlaxoSmithKline
• “A good practitioners discussion forum, well done!” Novartis
• “Right size, informative, some highlights, interesting discussions” Roche
•  “This event is an optimal platform to network and share experiences within the field of performance metrics” Grünenthal
• “Very good, good insight into relevant metrics and development trends for pharma companies and CROs” SGS
•  “Good coverage of wide range of topics” AstraZeneca
• “A very good networking opportunity, focused on high level definition of metrics” Chiesi Farmaceutics
• “Nice size of event for interactive discussion and knowledge sharing. Thought provoking“ Roche
• “Interesting concepts and discussion items” Sanofi Aventis
• “Good summary of current status – great networking opportunity” Medtronic Bakken
•  “Interesting workshop/conference, excellent possibility to share experience and lessons learned and to do networking” Baxter Innovations

Mark Newbury the Global Director of Performance & Analytics at Amgen UK will be joining Dave Zuckerman and Liz Wool on the Interactive Discussion session: Evaluating the true value of benchmarking data.

Mark has experience of working with a number of the leading providers of benchmarking tools and will bring a great deal of expertise and thought provoking topics to this interactive session.